Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC.ATOS · Entity 7556 | Chief Financial Officer | March 26, 2026 | March 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ATOSSA THERAPEUTICS, INC.
Report date March 26, 2026 · Filed March 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 63,000 |
Reported balance
After 2026-03-26 transaction · row 1
1 source rowRow 1 · 2026-03-26 · Grant · Acquired 63,000 · Balance 63,000 F1: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal annual installments on the first three anniversaries of March 26, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal annual installments on the first three anniversaries of March 26, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 26, 2026 Filed Mar 30, 2026 19:22 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantCommon Stock | 63,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-132644 · ownership.xml · nonDerivative · entry 1 Daniel Mark James · CIK 0002092593 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,000 F1 · shares: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal annual installments on the first three anniversaries of March 26, 2026. Read SEC document |
| October 14, 2025 Filed Oct 21, 2025 16:10 UTC | ATOSSA THERAPEUTICS, INC. ATOS · Entity 7556 | GrantStock Option (right to buy) · Derivative | 578,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001193125-25-245114 · ownership.xml · derivative · entry 1 Daniel Mark James · CIK 0002092593 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 578,000 Underlying: Common Stock · 578,000 shares Expires 2035-10-14 F1 · derivative.exercise_date: The options shall vest with respect to 25% on October 14, 2026, with the remaining 75% to vest in equal quarterly installments over the follwing three years, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.